Genelux
Westlake Village
About Genelux
Genelux Corporation is a privately-held, clinical-stage biopharmaceutical company that has developed a proprietary oncolytic virus-based technology platform and a deep pipeline of products with broad applications for cancer detection and therapy. GL-ONC1 the company’s lead oncology product candidate is an attenuated vaccinia virus (Lister strain) that results in dramatic regression and elimination of a wide range of solid tumors in animals without damaging healthy tissues or organs. GL-ONC1 encodes Green Fluorescent Protein (GFP) to enable highly selective imaging of tumors and metastases as an aid in the diagnosis and staging of cancer. GL-ONC1 is currently under evaluation in Phase I/II human clinical trials in the United States and Europe, and additional US and European-based trials are set to begin in the near future. GL-ONC1 is proving well-tolerated with minimal side effects and showing early signs of anti-tumor activity.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Public
- Employees: 11 – 50
- Estimated revenue: $1K – $10K
- Total funding: $129.5M
- Funding stage: IPO
- Last round: Post-IPO Equity (Jan 2026)
- Ticker: nasdaq:GNLX
- Website: genelux.com
- Phone: (805) 267-9889
Industries & Categories
Biopharma, Biotechnology, Health Care, Health Diagnostics
Social Profiles
Canonical: https://fsome.com/organization/genelux-32590 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.